Search
N,N-dimethylarginine
go.drugbank.com/drugs/DB01686ExperimentalIt is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid.
3'-phospho-5'-adenylyl sulfate
go.drugbank.com/drugs/DB02902Experimental3'-phospho-5'-adenylyl sulfate is a key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and r...
Aspartic acid
go.drugbank.com/drugs/DB00128ApprovedInvestigationalNutraceuticalOne of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
Flunisolide
go.drugbank.com/drugs/DB00180ApprovedFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...
Dipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Iodipamide
go.drugbank.com/drugs/DB04711ApprovedWithdrawnIodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Sodium copper chlorophyllin
go.drugbank.com/drugs/DB16522InvestigationalSCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.